^
Association details:
Biomarker:No biomarker
Cancer:Follicular Lymphoma
Drug:Ukoniq (umbralisib) (PI3Kδ inhibitor, Casein kinase I epsilon inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
02/05/2021
Excerpt:
UKONIQ is a kinase inhibitor indicated for the treatment of adult patients with...Relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.